Immix Biopharma, Inc. IMMX Deferred offering costs
Deferred offering costs at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredOfferingCosts.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s deferred offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s deferred offering costs?
- Immix Biopharma, Inc. (IMMX) reported deferred offering costs of $164.72K in Q1 2026.
- What is the long-term trend for Immix Biopharma, Inc.'s deferred offering costs?
- Over 2 years (2023 to 2025), Immix Biopharma, Inc.'s deferred offering costs has grown at a 3.6% compound annual growth rate (CAGR), from $87.23K to $93.63K.
- What does deferred offering costs mean?
- These are costs directly attributable to a planned equity or debt offering that are capitalized until the offering is completed. Once the financing occurs, these costs are typically reclassified as a reduction of the proceeds from the offering. This metric tracks the investment required to access capital markets.